Urovant Sciences (NASDAQ:UROV) announced its quarterly earnings data on Thursday. The company reported ($1.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.41), Fidelity Earnings reports.
UROV stock traded up $0.81 during midday trading on Friday, hitting $11.91. The company’s stock had a trading volume of 384 shares, compared to its average volume of 65,873. Urovant Sciences has a 12 month low of $6.45 and a 12 month high of $15.98. The company has a quick ratio of 6.65, a current ratio of 6.65 and a debt-to-equity ratio of 1.83. The firm has a market capitalization of $338.77 million, a price-to-earnings ratio of -3.30 and a beta of 2.01. The company has a 50 day moving average of $13.22 and a two-hundred day moving average of $10.70.
A number of brokerages recently issued reports on UROV. Zacks Investment Research upgraded Urovant Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 8th. HC Wainwright boosted their price objective on Urovant Sciences from $28.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Finally, ValuEngine upgraded Urovant Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, January 14th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $22.69.
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Further Reading: Using other technical indicators with support levels
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.